孟鲁司特治疗老年稳定期慢性阻塞性肺疾病患者的疗效分析

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (1): 66-70.

孟鲁司特治疗老年稳定期慢性阻塞性肺疾病患者的疗效分析

赵恬, 顾亮, 杜坚宗, 钦光跃

浙江医院呼吸内科,杭州 310012,浙江

收稿日期:2012-05-21 修回日期:2012-05-21 发布日期:2013-02-05
通讯作者: 钦光跃,通信作者,男,硕士,主任医师,主要研究方向:慢性阻塞性肺疾病,睡眠呼吸障碍疾病。 Tel: 0571-87987373 E-mail: hzqgy@126.com
作者简介:赵恬,女,硕士,主治医师,主要研究方向:慢性阻塞性肺疾病。 Tel: 13071850167 E-mail: zjzt2005@163.com
基金资助:
浙江省医药卫生科技计划项目(2007B018)

Analysis of therapeutic effect of montelukast in elderly stable patients with moderate on severe chronic obstructive pulmonary disease

ZHAO Tian, GU Liang, DU Jian-zong, QIN Guang-yue

Department of Respiratory, Zhejiang Hospital, Hangzhou 310013, Zhejiang, China

Received:2012-05-21 Revised:2012-05-21 Published:2013-02-05

摘要/Abstract

摘要： 目的: 评价孟鲁司特治疗老年稳定期中重度慢性阻塞性肺疾病(COPD)患者的疗效及安全性。方法: 60例男性稳定期中重度COPD患者随机分为治疗组和对照组,在规则吸入布地奈德联合福莫特罗(信必可都保)的基础上,治疗组加服孟鲁司特,疗程6个月。比较两组患者治疗前后基础呼吸困难指数(BDI)、圣乔治呼吸问卷(SGRQ)评分、肺功能、诱导痰细胞分类及白三烯B₄(LTB₄)水平。结果: 47例患者完成试验,期间未发生孟鲁司特相关严重药物不良反应。两组患者经治疗后BDI均升高,SGRQ评分及诱导痰中性粒细胞百分比均下降(P<0.05),但肺功能均无明显改善(P>0.05)。与对照组相比,治疗组患者诱导痰中嗜酸性粒细胞百分比下降,且BDI、SGRQ评分、诱导痰LTB₄水平的改善作用更明显,两组改善率差异有统计学意义(P<0.05) 。结论: 孟鲁司特作为老年稳定期中重度COPD患者的补充治疗安全有效。

关键词: 孟鲁司特, 白三烯受体拮抗剂, 慢性阻塞性肺疾病, 疗效

Abstract: AIM: To evaluate the efficacy and safety of montelukast in elderly patients affected by stable moderate to severe chronic obstructive pulmonary disease(COPD). METHODS: In this randomized, prospective, single-blind, and controlled study, 60 COPD patients treated with formoterol plus budesonide were randomized to receive treatment of oral montelukast for 6 months(montelukast group) or not(control group).The baseline dyspnea index(BDI), the St George's Respiratory Questionnaire (SGRQ) scores, pulmonary function tests(PFTs), induce sputum and the levels of LTB₄ were compared before and after the treatment in two groups.RESULTS: 47 patients had completed the study, no severe montelukast relevant side effects were reported during the observation period. After the treatment,the BDI was increased in the two groups,but the SGRQ score and the percentage of neutrophil of induced sputum were decreased(P<0.05),the pulmonary functions were not markedly improved(P>0.05). Compared with the control group,the percentage of neutrophils of induced sputum in montelukast group was decreased;the BDI,the SGRQ score,the levels of LTB₄ had significant improvement,there were statistically significant difference(P<0.05).CONCLUSION: The treatment of montelukast added to inhaled budesonide and formoterol in elderly stable patients with moderate to severe COPD is effective and safe.

Key words: Montelukast, Leukotriene receptor antagonist, Chronic obstructive pulmonary disease, Therapeutic effect

中图分类号:

R563

赵恬, 顾亮, 杜坚宗, 钦光跃. 孟鲁司特治疗老年稳定期慢性阻塞性肺疾病患者的疗效分析[J]. 中国临床药理学与治疗学, 2013, 18(1): 66-70.

ZHAO Tian, GU Liang, DU Jian-zong, QIN Guang-yue. Analysis of therapeutic effect of montelukast in elderly stable patients with moderate on severe chronic obstructive pulmonary disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 66-70.

参考文献

[1] 马陆,郭晓渊,皮文霞. 孟鲁司特钠治疗婴幼儿非特应性喘息症的疗效分析[J]. 中国临床药理学与治疗学,2011,16(11):1300-1303.
[2] GP Currie, P Srivastava, OJ Dempsey, et al. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists[J]. QJM, 2005, 98(3):171-182.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志, 2007, 30(1):8-17.
[4] Donald AM, David HW, Carolyn KW, et al.The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes[J]. Chest, 1984,85(6):751-758.
[5] Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire[J]. Respir Med, 1991, 85 Suppl B: 25-31.
[6] Calverley PM, Anderson JA, Celli B, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J]. N Engl J Med, 2007,356(8):775-789.
[7] Usery JB, Self TH, Muthiah MP, et al.Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease[J]. Pharmacotherapy, 2008, 28(9): 1183-1187.
[8] Rubinstein I, Kumar B, Schriever C,et al.Long-term montelukast therapy in moderate to severe copd-a preliminary observation[J]. Respir Med,2004,98(2):134-138.
[9] Celik P, Sakar A, Havlucu Y, et al.Short-term effects of montelukast in stable patients with moderate to severe COPD[J]. Respir Med ,2005,99(4):444-450.
[10] Vaquerizo MJ, Casan P, Castillo J, et al.Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma[J]. Thorax , 2003,58(3):204-210.
[11] Usery JB, Self TH, Muthiah MP,et al.Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease[J]. Pharmacotherapy, 2008,28(9):1183-1187.
[12] Nicolo Gueli, Walter Verrusio, Adele Linguanti, et al.Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): A preliminary report[J]. Arch Gerontol Geriatr, 2011,52(1):e36-e39.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[4]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[5]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[6]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[7]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[8]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[9]	赵倩，杨广，曹莉华，于陈宝. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 182-188.
[10]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[11]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[12]	尹子毅，王峰，赵梦，张铁，王丕琳. 卡培他滨为基础一线方案治疗Her2阴性转移性乳腺癌的单中心回顾性研究及TYMP基因多态性分析[J]. 中国临床药理学与治疗学, 2019, 24(9): 1002-1008.
[13]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[14]	朱悚之. 人纤维蛋白原对急诊外伤致创伤性凝血病疗效及相关因素分析[J]. 中国临床药理学与治疗学, 2019, 24(6): 693-698.
[15]	郭良堂，林超，孙云，戴盛锋，张炳才，陈舒. 二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 554-560.